Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilars and to the discovery and development of novel therapeutics for autoimmune indications. In July 2010, Momentaâs lead product (developed in collaboration with Sandoz) was approved as the first generic version of LOVENOXÂŽ (Enoxaparin Sodium Injection). In April 2015, the company announced the FDA approval of once daily GlatopaÂŽ 20 mg/mL (glatiramer acetate injection), a fully substitutable generic version of COPAXONEÂŽ 20 mg/mL. Glatopa was also developed in collaboration with Sandoz. The company's development pipeline includes a biosimilar version of HUMIRAÂŽ (adalimumab), a biosimilar version of ORENCIAÂŽ (abatacept) and a portfolio of five other early stage biosimilar programs in collaboration with Mylan and three novel drug candidates for autoimmune indications. Source
No articles found.
Our strategy is to be known as âthe prostate cancer companyâ. We aspire to be ...
Our strategy is to be known as âthe prostate ...
We are a clinical stage biopharmaceutical company leveraging our two proprietary t...
We are a clinical stage biopharmaceutical compa...
MacroGenics is a clinical-stage biopharmaceutical company focused on discovering a...
MacroGenics is a clinical-stage biopharmaceutic...
IVERIC bio is a gene therapy focused company developing innovative treatments for ...
IVERIC bio is a gene therapy focused company de...
Portola Pharmaceuticals is a global, commercial-stage biopharmaceutical company fo...
Portola Pharmaceuticals is a global, commercial...
LifeVantage Corporation (Nasdaq: LFVN) is a pioneer in Nutrigenomics - a new scien...
LifeVantage Corporation (Nasdaq: LFVN) is a pio...
TG Therapeutics is a biopharmaceutical company focused on the acquisition, develop...
TG Therapeutics is a biopharmaceutical company ...
Join the National Investor Network and get the latest information with your interests in mind.